Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy
Open Access
- 1 January 2013
- journal article
- clinical trial
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2013, 1-12
- https://doi.org/10.1155/2013/195691
Abstract
Objective. To evaluate the efficacy of autologous cytokine-induced killer (CIK) cells in patients with renal cell carcinoma (RCC). Methods. 20 patients diagnosed with TNM stage I or II RCC were randomly divided into two groups, a CIK cell treatment group and a control group. The endpoint was progression-free survival (PFS) evaluated by Kaplan-Meier analyses. Results. CD3+, CD3+/CD8+, CD3+/CD4+, and CD3+/CD56+ levels increased after CIK cell culture (). The median PFS in CIK cell treatment group was significantly longer than that in control group (PFS, 32.2 months versus 21.6 months; log-rank, ), all patients were alive during the course of followup, and there are no statistically significant differences between two groups in OS (log-rank, ). Grade III or greater adverse events were not observed. Conclusions. CIK cells treatment could prolong survival in patients with RCC after radical nephrectomy and showed acceptable curative effect with potential enhancement of cellular immune function. This trial is registered with Clinicaltrials.gov NCT01799083.Funding Information
- National Natural Science Foundation of China (31270820, 81230061, 81121004, 2012CB518103)
This publication has 40 references indexed in Scilit:
- Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinomaBritish Journal of Cancer, 2013
- Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)Zeitschrift für Krebsforschung und Klinische Onkologie, 2010
- T Cell–Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future PerspectiveClinical Cancer Research, 2009
- Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN-α2a Therapy in Metastatic Renal Cell Carcinoma PatientsClinical Cancer Research, 2009
- Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFNα in Patients with Good Prognosis Metastatic Renal CancerClinical Cancer Research, 2008
- Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriersInternational Immunology, 2008
- TNF-α is critical for antitumor but not antiviral T cell immunity in miceJCI Insight, 2007
- Recognition of Breast Cancer Cells by CD8+ Cytotoxic T-Cell Clones Specific for NY-BR-1Cancer Research, 2006
- Synergistic Antitumor Effects of Immune Cell-Viral BiotherapyScience, 2006
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986